Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

* Inclusion criteria * 18 \< Age \< 80 * AF diagnosed by ECG at any time prior to enrollment * Moderate or severe mitral valve stenosis diagnosed by echocardiography at any time prior to enrollment * Exclusion criteria * Refusal to consent * Transient AF due to reversible cause (Postoperative, ongoing systemic inflammation, thyrotoxicosis) * Patients undergoing mechanical valve replacement * Coagulopathy * Hepatic impairment with significant bleeding risk * High bleeding risk due to following disease or condition diagnosed within 1 month prior to randomization * GI ulcer or bleeding, Esophageal or gastric varix, Malignancy, Brain or cord injury, Surgery for brain, spinal cord, opthalmic, Intracranial hemorrhage, Arteriovenous malformation, Vascular aneurysms, Brain or spinal vascular disorder * Stroke, Systemic arterial thromboembolism, Acute myocardial infarction diagnosed within 14 days prior to randomization * End stage kidney disease (CrCL \< 15mL/min) or Dialysis * Severe hypertension * Alcohol abuse or other psychiatric disease * Epidural puncture or anesthesia * Pulmonary thromboembolism with hemodynamical instability requiring thrombolysis or thrombectomy * Pregnant or lactating women * Allergy to edoxaban or warfarin * Ongoing need for other anticoagulant or clarithromycin, rifampin) * Participants for other trials within 1 month prior to enrollment * Other patients to be inappropriate to participate in the trial determined by the investigator